Till­man Gern­gross

As mar­ket volatil­i­ty sweeps through the land­scape, CEO changes are re­al­ly ramp­ing up, and top­ping the list is Till­man Gern­gross, a force in the an­ti­body space who hitched his wag­on to find­ing an­oth­er Covid-19 so­lu­tion by co-found­ing Ada­gio Ther­a­peu­tics. With big in­vestors back­ing him, the big dreams sput­tered when ADG20 proved less ef­fec­tive against Omi­cron in De­cem­ber. Gern­gross has now re­signed as CEO, hand­ing things over to COO David Her­ing on an in­ter­im ba­sis un­til a per­ma­nent suc­ces­sor is named. No stranger to the Covid vac­cine fight, Her­ing was poached from his role as glob­al mR­NA busi­ness lead of Pfiz­er in Ju­ly 2021.

The pan­dem­ic threw a wrench in Jeff Mar­raz­zo’s plans to ex­it Spark ear­li­er, while the com­pa­ny set­tled in as a whol­ly-owned sub­sidiary of Roche. But the found­ing CEO feels the time is right to walk away from the Lux­tur­na mak­er on April 1 and hand things over to Pfiz­er alum Ron Philip, the COO for the last year and a Spark ex­ec since 2017. For Mar­raz­zo, an­oth­er CEO gig isn’t on the hori­zon: “I’m look­ing to move from be­ing very deep, as I’ve been for the last 11 years at Spark, to be­ing broad­er and work­ing with a mul­ti­tude of dif­fer­ent lead­ers and founders that are try­ing to do things,” he told End­points News.

Al­though specifics weren’t dis­closed as to why Mark Rothera stepped down from Si­lence Ther­a­peu­tics this week, our Max Gel­man points out that Craig Tooman’s M&A bona fides could be a de­ter­min­ing fac­tor as to why he suc­ceed­ed him — two weeks re­moved from re­leas­ing a study of its siR­NA can­di­date SLN360 for heart dis­ease. Tooman, tak­ing the job af­ter a year as Si­lence’s fi­nance chief, was pre­vi­ous­ly CEO of Lea­wood, KS-based an­i­mal health com­pa­ny Aratana Ther­a­peu­tics un­til it merged with Elan­co in 2019. He was al­so CFO and COO at Vy­ome Ther­a­peu­tics.

Kristi Jones

Scott Carmer ten­dered his res­ig­na­tion last week at T cell im­munother­a­py play­er Nex­Im­mune a year af­ter its Nas­daq de­but, and the Gaithers­burg, MD biotech has filled the va­can­cy by pro­mot­ing Big Phar­ma vet Kristi Jones to CEO. Jones, the CBO at Nex­Im­mune the past four years, was VP of glob­al strate­gic mar­ket­ing and then head of port­fo­lio strat­e­gy and man­age­ment at As­traZeneca from 2013-15. Fur­ther back, Jones spent 16 years at Genen­tech/Roche in such roles as head of im­munol­o­gy and oph­thal­mol­o­gy in glob­al port­fo­lio and prod­uct strat­e­gy.

Fi­nal­ly in our crop of CEO tran­si­tions, Vic­to­ria Ri­chon has stepped down at Ri­bon Ther­a­peu­tics, but this isn’t good­bye. She’ll be an R&D ad­vi­sor to the board of di­rec­tors and will chair the sci­en­tif­ic ad­vi­so­ry board as Prakash Ra­man takes over the top spot. Be­fore his re­cent stint at Flag­ship Pi­o­neer­ing as se­nior part­ner, chief busi­ness de­vel­op­ment of­fi­cer, Ra­man was VP, glob­al head of busi­ness de­vel­op­ment and li­cens­ing at the No­var­tis In­sti­tutes for Bio­med­ical Re­search. The PARP in­hibitor RBN-2397 is the lead pro­gram at Ri­bon, which hit pay­dirt in Ju­ly 2021 with a $65 mil­lion Se­ries B1 round.

Brent Warn­er

→ Po­sei­da just hooked a big fish from the No­var­tis pond, catch­ing Brent Warn­er and nam­ing him pres­i­dent of gene ther­a­py. In his pre­vi­ous post, Warn­er was the Swiss phar­ma’s VP of gene ther­a­py and rare dis­ease, and his ap­point­ment is piv­otal to Po­sei­da’s gene ther­a­py al­liance with Take­da from Oc­to­ber 2021 which could pro­duce up to eight can­di­dates. Up first is he­mo­phil­ia A, and Warn­er has ex­pe­ri­ence with this in­di­ca­tion as US com­mer­cial leader for val­rox at Bio­Marin, who’s giv­ing the drug an­oth­er go with the FDA fol­low­ing its CRL in 2020. Warn­er’s ar­rival comes af­ter Er­ic Os­tertag passed the CEO torch to Mark Ger­gen on Feb. 1.

Robert La­Caze

→ This com­ing Tues­day, Chris­tine Roth will lead the on­col­o­gy strate­gic busi­ness unit at Bay­er’s phar­ma­ceu­ti­cals di­vi­sion, suc­ceed­ing Robert La­Caze. And on May 1, La­Caze has his next move all lined up, lead­ing a biotech of his own at Mnemo Ther­a­peu­tics, a French T cell ther­a­py play­er with Michel Sade­lain as one of its sci­en­tif­ic co-founders. La­Caze spent 26 years at Bris­tol My­ers Squibb be­fore jump­ing to Bay­er and will re­place found­ing CEO Alain Maiore, who tran­si­tions to COO once La­Caze takes over.

Pa­tri­cia Jud­son

→ Al­though Karyopharm put its Xpovio da­ta through the pos­i­tive spin cy­cle a cou­ple weeks ago, an­a­lysts were less than im­pressed, and now comes word that CMO Jatin Shah is out in or­der “to pur­sue oth­er pro­fes­sion­al op­por­tu­ni­ties, but will con­tin­ue to serve Karyopharm in an ad­vi­so­ry ca­pac­i­ty.” In the mean­time, Karyopharm has brought in Pa­tri­cia Jud­son as SVP of med­ical strat­e­gy and Stu­art Poul­ton as SVP of strat­e­gy and port­fo­lio man­age­ment. At As­traZeneca, Jud­son was US med­ical head for the DNA dam­age re­sponse fran­chise in women’s on­col­o­gy, and she then jumped to Glax­o­SmithK­line as glob­al head of women’s on­col­o­gy, med­ical af­fairs. Poul­ton worked for Eli Lil­ly and Am­gen for more than a decade each and comes from Ab­b­Vie, where he was VP of clin­i­cal de­vel­op­ment op­er­a­tions.

Tr­isha Mil­li­can

→ It hasn’t been peach­es and cream for Metacrine these days, jet­ti­son­ing half its work­force a cou­ple weeks ago and piv­ot­ing to IBD af­ter strik­ing out on NASH. The Rich Hey­man-chaired biotech now has its sec­ond C-suite de­par­ture to con­tend with in two months as CFO Tr­isha Mil­li­can re­signs. While she helps with the tran­si­tion un­til March 31, Michael York gets the bump from SVP, busi­ness de­vel­op­ment and com­mer­cial strat­e­gy to CBO. At the end of 2021, Hu­bert Chen re­signed as Metacrine’s CMO to take the same job at ADARx Phar­ma­ceu­ti­cals.

→ Buf­fa­lo’s own Athenex has tapped Joe An­noni as CFO, re­plac­ing Ran­doll Sze, who turned in his walk­ing pa­pers last Au­gust. Since 2010, An­noni had been man­ag­ing di­rec­tor of GFW Part­ners be­fore join­ing Athenex, whose stock tanked in March 2021 when the FDA brought down the CRL ham­mer on its breast can­cer drug, oral pa­cli­tax­el and ence­quidar. The ac­qui­si­tion of Ku­ur Ther­a­peu­tics the fol­low­ing May did lit­tle to dra­mat­i­cal­ly turn things around as Athenex falls deep­er in­to pen­ny stock ter­ri­to­ry, and it’s up to An­noni to stem the tide.

Sarah Yuan

→ Still un­der a clin­i­cal hold that was trig­gered in Ju­ly for its he­mo­phil­ia A pro­gram, Flag­ship’s Sig­ilon Ther­a­peu­tics has ap­point­ed Sarah Yuan as chief tech­ni­cal op­er­a­tions of­fi­cer. When blue­bird bio split in half, Yuan shift­ed over to 2sev­en­ty bio as VP of process and an­a­lyt­i­cal de­vel­op­ment af­ter hold­ing that post at blue­bird since Ju­ly 2019. Ear­li­er, the 10-year Bio­gen vet was head of man­u­fac­tur­ing for the rare blood dis­or­ders fran­chise at Sanofi fol­low­ing the buy­out of Biover­a­tiv, where she was head of tech­ni­cal de­vel­op­ment and man­u­fac­tur­ing sci­ences.

Gi­na Maz­zariel­lo

→ Amy­lyx is get­ting its le­gal ducks in a row be­fore its June 29 PDU­FA date and the FDA’s Pe­riph­er­al and Cen­tral Ner­vous Sys­tem Drugs ad­comm that will con­vene March 30 to dis­cuss the ALS drug AMX0035. Gi­na Maz­zariel­lo has been se­lect­ed as chief le­gal of­fi­cer and gen­er­al coun­sel af­ter a num­ber of roles at Boehringer In­gel­heim that spanned near­ly 15 years; she had been the Ger­man com­pa­ny’s VP, hu­man phar­ma busi­ness law since 2015. A rub­ber stamp here would give Josh Co­hen and Justin Klee on­ly the third ap­proval for an ALS ther­a­py since 1995.

Elis­a­beth Crön­ert-Ben­dell

→ Feel the beat of the Rhythm of the night, or in this case, the Rhythm of pro­mo­tions: David Meek­er’s Rhythm Phar­ma­ceu­ti­cals has doled out new gigs to Joe Shul­man (chief tech­ni­cal of­fi­cer), Patrick Kleyn (SVP and head of trans­la­tion­al R&D), and Elis­a­beth Crön­ert-Ben­dell (SVP and head of strat­e­gy). In 2020, Shul­man was ush­ered in­to the squad as SVP of tech­ni­cal op­er­a­tions from Ra Phar­ma­ceu­ti­cals, where he held that very po­si­tion be­fore UCB came along for a $2.1 bil­lion buy­out. Kleyn, the di­rec­tor of ex­ter­nal in­no­va­tion dur­ing a six-year tenure with EMD Serono, joined Rhythm in 2018 and had been in­ter­im head of the trans­la­tion­al R&D team. The new­bie of the bunch and a 10-year Sanofi vet, Crön­ert-Ben­dell gets pro­mot­ed here to SVP af­ter a year as VP and head of in­ter­na­tion­al strat­e­gy.

Steve Hugh­es

→ Avid­i­ty Bio­sciences, where Art Levin is lead­ing the sci­ence on the de­vel­op­ment of an­ti­body oligonu­cleotide con­ju­gates, has brought on Steve Hugh­es as CMO. Hugh­es, the ex-med­ical chief and cur­rent strate­gic med­ical ad­vi­sor for Arc­turus Ther­a­peu­tics, was chief de­vel­op­ment of­fi­cer at Io­n­is af­ter its name change in 2015 and made ear­li­er stops at Io­n­is part­ner Bio­gen (med­ical di­rec­tor, on­col­o­gy) and CSL Behring (med­ical af­fairs co­or­di­na­tor, West­ern Eu­rope).

Eliz­a­beth Mont­gomery

→ Tempt­ing though it may be, Peer Re­view will es­chew the “Be­witched” ref­er­ences and just say that Eliz­a­beth Mont­gomery has tak­en on the role of chief peo­ple of­fi­cer at Black Di­a­mond Ther­a­peu­tics, which has ex­pe­ri­enced its share of lead­er­ship turnover of late. Mont­gomery held the same role at ClearView Health­care Part­ners be­fore head­ing to a crew that has seen the ter­mi­na­tion of CMO Rachel Humphrey and the res­ig­na­tions of CSO Chris Roberts and CFO Thomas Leggett in the last year.

John Gold­berg

→ John Gold­berg has been pro­mot­ed to CMO at On­corus, whose lead pro­gram ON­CR-177 is an on­colyt­ic HSV-1 tar­get­ing sev­er­al can­cers. Gold­berg first start­ed at On­corus in Oc­to­ber 2018 as SVP of clin­i­cal de­vel­op­ment, and pri­or to that, he was se­nior med­ical di­rec­tor at H3 Bio­med­i­cine.

→ Last month, Avenge Bio came on the biotech scene with $45 mil­lion in Se­ries A fund­ing, and this week the Nat­ick, MA-based im­munother­a­py play­er an­nounced that Dou­glas Carl­son has joined their ranks as COO and CFO. Pri­or to join­ing Avenge — which was co-found­ed by CEO Michael Hef­fer­nan, Rice Uni­ver­si­ty’s Omid Veiseh and Ob­sid­i­an chief Paul Wot­ton — Carl­son was COO, CFO and chief com­pli­ance of­fi­cer of Ike­na On­col­o­gy. He al­so served as VP, com­mer­cial op­er­a­tions and VP, cor­po­rate strat­e­gy & busi­ness de­vel­op­ment at Col­legium Phar­ma­ceu­ti­cal.

Klaus Wag­n­er

→ Zach Horn­by is hir­ing up a storm at San Diego’s Bound­less Bio, fill­ing a cru­cial po­si­tion with Klaus Wag­n­er as CMO. The Genen­tech and Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter alum had logged sev­en years as the med­ical chief at In­hi­brx. There’s cer­tain­ly been a bound­less amount of new faces at Bound­less Bio in the last year alone, no­tably pick­ing up CBO Neil Ab­dol­lahi­an from Cidara Ther­a­peu­tics and ap­point­ments al­so rang­ing from gen­er­al coun­sel to VP of pre­ci­sion med­i­cine.

→ Feng Zhang spin­out Ar­bor Biotech­nolo­gies, the CRISPR play­er which signed on the dot­ted line with Ver­tex on a $1.2 bil­lion cell ther­a­py deal and then put to­geth­er a $215 mil­lion Se­ries B haul last year, has tapped Steven Faval­oro as CFO. Faval­oro has been a fi­nance chief be­fore at Ar­ran­ta Bio and CD­MO Bram­mer Bio, which Ther­mo Fish­er pur­chased in March 2019.

Andy Holt

→ Ncar­dia, a Dutch-Bel­gian biotech fo­cused on in­duced pluripo­tent stem cells (iP­SCs), has ap­point­ed Andy Holt as COO. Pri­or to join­ing Ncar­dia, Holt served as EVP, com­mer­cial de­vel­op­ment and man­u­fac­tur­ing at AskBio as well as its CD­MO sub Vi­ral­gen. Ear­li­er in this ca­reer, Holt al­so took on roles in busi­ness de­vel­op­ment and man­age­ment at Mil­li­pore­Sig­ma and Lon­za.

Mary Pao

→ ANI Phar­ma­ceu­ti­cals out of Min­neso­ta is bulk­ing up its rare dis­ease busi­ness unit with Mary Pao as CMO and Eliz­a­beth Pow­ell as chief com­pli­ance of­fi­cer and head of le­gal. Pao worked on Rit­ux­an at Genen­tech, was a glob­al med­ical af­fairs lead at GSK and led clin­i­cal af­fairs at W20 Group un­til May 2021. Pow­ell’s long ca­reer at Mer­ck be­gan in 1997, cul­mi­nat­ing in her role as man­ag­ing coun­sel and ex­ec­u­tive di­rec­tor, US com­mer­cial & com­pli­ance le­gal be­fore mov­ing on to ANI, which bought gener­ics com­pa­ny Novi­tium Phar­ma al­most a year ago for up to $210 mil­lion.

Mark Farmery

→ Bri­an McGee has signed on to be CBO of Swedish TCR play­er Anoc­ca, while Mark Farmery gets el­e­vat­ed to chief de­vel­op­ment of­fi­cer. McGee owns Big Phar­ma ex­pe­ri­ence from com­mer­cial, fi­nance and strat­e­gy roles at GSK and was a part­ner at Lon­don con­sult­ing firm No­va­sec­ta. An As­traZeneca busi­ness de­vel­op­ment vet, Farmery had been VP of BD at Anoc­ca since May 2020 be­fore gain­ing this pro­mo­tion.

→ George Chi has joined the ex­ec­u­tive team at Ta­vo mak­er On­coSec as CFO. On­coSec hasn’t found a per­ma­nent CEO since the de­par­ture of Daniel O’Con­nor, with Bri­an Leuth­n­er serv­ing briefly as in­ter­im CEO last year and Kevin Smith now tak­ing the role as in­ter­im pres­i­dent and chief ex­ec­u­tive. Speak­ing of CEOs, Chi held that ti­tle at TH­Plas­ma since Ju­ly 2020 be­fore tak­ing on this role at On­coSec.

→ Last year was huge for syn­bio up­start An­theia, net­ting a $73 mil­lion Se­ries B in June and part­ner­ing with Gink­go short­ly there­after. This week Christi­na Smolke has ex­pand­ed the team with Hei­di Pu­cel, who brings her HR acu­men as chief peo­ple of­fi­cer. Pu­cel al­so took on this very role at Countsy, an ac­count­ing firm geared to­ward star­tups, for near­ly five years.

Lisa Beck

→ Fred­er­ick, MD-based Ve­r­alox Ther­a­peu­tics, de­vel­op­ing a 12-lipoxy­ge­nase (12-LOX) in­hibitor named VLX-1005 for he­parin-in­duced throm­bo­cy­tope­nia, has turned to Lisa Beck to be CBO. Beck spent near­ly 24 years at GSK and lat­er jumped to Alex­ion, where she was ex­ec­u­tive di­rec­tor and head of glob­al busi­ness de­vel­op­ment trans­ac­tions and al­liance man­age­ment. In 2018 she shift­ed to Brii Bio­sciences, serv­ing as VP of busi­ness de­vel­op­ment be­fore climb­ing to SVP, busi­ness de­vel­op­ment and port­fo­lio strat­e­gy.

Adri­an Quar­tel

→ New­ton, MA rare dis­ease biotech Ac­er Ther­a­peu­tics has re­cruit­ed ex-Bio­Marin glob­al med­ical af­fairs head Adri­an Quar­tel as CMO. Since 2020 Quar­tel had been med­ical chief at Adamas Phar­ma­ceu­ti­cals, whose Parkin­son’s port­fo­lio was en­tic­ing enough to Su­per­nus to plunk down more than $400 mil­lion for the com­pa­ny in Oc­to­ber 2021. Ac­er is look­ing at a June 5 PDU­FA date for its lead pro­gram AC­ER-001 to treat urea cy­cle dis­or­ders (UCDs).

→ UK-based Myricx Phar­ma is bring­ing aboard some fresh faces to its lead­er­ship team with the ap­point­ments of Za­hid Bashir as CMO, Richard Rut­ter as head of bi­ol­o­gy and Francesco Fal­ciani as head of bioin­for­mat­ics. Bashir has led suc­cess­ful ca­reers at Roche, GSK, Kite, Bris­tol My­ers and As­traZeneca. Mean­while, Rut­ter for­mer­ly served as di­rec­tor of bi­ol­o­gy at the Glax­o­SmithK­line Neu­rode­gen­er­a­tion Re­search Unit in Sin­ga­pore and was the CSO of Au­spher­ix. Fi­nal­ly, Fal­ciani pre­vi­ous­ly had a stint at Glax­oW­ell­come as bioin­for­mat­ics group leader and was head of tar­get dis­cov­ery at Lo­ran­tis.

Rod­er­ick Scott

→ To the east­ern tip of Cana­da we go, where New­found­land and Labrador-based Se­quence Bio has wel­comed Rod­er­ick Scott as chief sci­ence of­fi­cer. Scott was em­ploy­ee No. 1 at He­li­con Ther­a­peu­tics, where he was di­rec­tor of dis­cov­ery sys­tems, and more re­cent­ly he’s been VP of re­search at Lead­ing Bio­Sciences, the com­pa­ny that merged with Seneca Bio­phar­ma to be­come Pal­isade Bio.

→ Fe­masys — fo­cused on meet­ing women’s needs — has brought on Dov Ele­fant as the com­pa­ny’s first-ever CFO. Ele­fant most re­cent­ly served in the same ca­pac­i­ty at Cel­lec­tar Bio­sciences and held the same role at Cel­sus Ther­a­peu­tics and Al­thera Med­ical.

→ Eye­Y­on Med­ical — fo­cused on the de­vel­op­ment of oph­thalmic med­ical de­vices — has wel­comed Sharon Bakalash to the fold as CMO. Bakalash comes with ex­pe­ri­ence from her times at Tis­sue­Gen, No­var­tis and Al­con.

Anne-Marie Li-Kwai-Che­ung

→ Mod­i­fy­ing its R&D al­liance with Take­da last fall, Wave Life Sci­ences has called up­on Anne-Marie Li-Kwai-Che­ung to be SVP, reg­u­la­to­ry af­fairs, com­pli­ance and pol­i­cy. Li-Kwai-Che­ung has held reg­u­la­to­ry po­si­tions at Gen­zyme, GSK, and re­cent­ly at Roche as life­cy­cle leader for tomin­ersen — the Hunt­ing­ton’s drug that Roche is try­ing to res­ur­rect af­ter a dis­as­trous Phase III tri­al. Wave’s wipe­outs with Hunt­ing­ton’s have been well-doc­u­ment­ed too, as two drugs for the dis­ease cir­cled the drain in March 2021.

→ Men­lo Park, CA-based PacBio is bring­ing in Michael Eber­le to the pack as VP of com­pu­ta­tion­al bi­ol­o­gy. Eber­le joins af­ter a 15-year stint at Il­lu­mi­na, where he most re­cent­ly served as VP and dis­tin­guished sci­en­tist.

→ Macrophage-fo­cused En­livex Ther­a­peu­tics has brought on Einat Galami­di as VP, med­ical. Galami­di comes aboard af­ter a decade stint at Gami­da Cell, where she most re­cent­ly served as VP of clin­i­cal de­vel­op­ment. Dur­ing her time at Gami­da, Galami­di led clin­i­cal de­vel­op­ment for po­ten­tial cell ther­a­py omidu­bi­cel — a po­ten­tial bone mar­row trans­plant so­lu­tion for pa­tients with blood can­cers.

Nan­cy Miller-Rich

→ With their lat­est round of cash sewn up last May and for­mer CRISPR Ther­a­peu­tics ex­ec Philippe Drou­et in his first year as CEO, pro­tein degra­da­tion out­fit Bio­Th­eryX has made Nan­cy Miller-Rich chair of the board. Up­on her re­tire­ment from Mer­ck in Sep­tem­ber 2017, Miller-Rich was SVP, glob­al busi­ness de­vel­op­ment and li­cens­ing, strat­e­gy and com­mer­cial sup­port for the Hu­man Health busi­ness. She’s al­so on the boards of In­ter­cept, Aldeyra Ther­a­peu­tics, 4D Mol­e­c­u­lar Ther­a­peu­tics and At­tralus.

George Church

→ In­te­gra Ther­a­peu­tics — a biotech look­ing to cre­ate next-gen gene writ­ing tools  — has at­tract­ed a big name on­to its SAB with George Church. In his star-stud­ded ca­reer, Church helped ini­ti­ate the Hu­man Genome Pro­ject in 1984 and the Per­son­al Genome Pro­ject in 2005 and demon­strat­ed that CRISPR/Cas9 could be used to ed­it hu­man stem cells. Church cur­rent­ly serves as pro­fes­sor of ge­net­ics at Har­vard Med­ical School and pro­fes­sor of health sci­ences and tech­nol­o­gy at Har­vard and MIT.

→ UK ge­nomics com­pa­ny Rev­olu­Gen has tapped An­nal­isa Jenk­ins as chair of its board of di­rec­tors. Jenk­ins brings with her a wealth of ex­pe­ri­ence to the role while cur­rent­ly serv­ing on the boards of Af­fimed, Avro­bio, Co­coon Biotech, Com­pass Path­ways, Oncim­mune and Ori Biotech to name a few. Jenk­ins pre­vi­ous­ly held long ca­reers at Mer­ck Serono (EVP, head of glob­al de­vel­op­ment) and Bris­tol My­ers (SVP and head of glob­al med­ical af­fairs).

Ru­by Chandy

→ Ru­by Chandy will be added to the board of di­rec­tors at Ther­mo Fish­er on March 1, mak­ing it a bak­er’s dozen in a board that in­cludes Ed­i­tas Med­i­cine CEO Jim Mullen and Tyler Jacks. Chandy, the ex-Dow chief mar­ket­ing of­fi­cer, has board seats at DuPont and Flowserve.

→ San Diego-based Abili­ta Bio is mak­ing room on its board of di­rec­tors for Daniel Brad­bury. Brad­bury cur­rent­ly serves as ex­ec­u­tive chair­man of Equi­l­li­um and pre­vi­ous­ly had an 18-year stint as pres­i­dent, CEO and di­rec­tor of Amylin Phar­ma­ceu­ti­cals. This is far from Brad­bury’s first rodeo in a board ca­pac­i­ty. He cur­rent­ly sits on the boards of Bio­con, Cas­tle Bio­sciences, Equi­l­li­um and In­ter­cept, among oth­ers.

→ Almi­rall is los­ing its chair­man of the board Jorge Gal­lar­do Bal­lart as he plans for re­tire­ment. The com­pa­ny has nom­i­nat­ed Car­los Gal­lar­do Piqué (Almi­rall’s VP of the board) as his suc­ces­sor. Piqué jump­start­ed his ca­reer at Pfiz­er, spend­ing near­ly a decade there be­fore join­ing Almi­rall and serv­ing as gen­er­al man­ag­er of the UK and Ire­land be­fore part­ing ways with the com­pa­ny in 2013. In ad­di­tion, Piqué is the founder and CEO of CG Health Ven­tures.

Mor­rey Atkin­son

→ Or­biMed-backed NASH play­er 89bio has brought Mor­rey Atkin­son in­to the fold as a mem­ber of its board. The head of com­mer­cial man­u­fac­tur­ing and sup­ply chain at Ver­tex since June 2020, Atkin­son spent eight years at Bris­tol My­ers and an­oth­er nine at Eli Lil­ly in man­u­fac­tur­ing roles.

→ Af­ter com­plet­ing its re­cent IPO, Ed­in­burgh-based TC Bio­pharm — the com­pa­ny that bagged $16 mil­lion and teamed up with blue­bird back in 2017 to take on gam­ma delta T cells — is en­list­ing four new mem­bers for its board of di­rec­tors: Mark Bony­ha­di (se­nior ad­vi­sor at Qim­ing Ven­ture Part­ners USA); James Cul­ver­well (chair­man of HOX Ther­a­peu­tics); Ar­lene Mor­ris (non-ex­ec­u­tive di­rec­tor at Co­gent Bio­sciences, Virid­i­an Ther­a­peu­tics and Palatin Tech­nolo­gies); and Ed Niem­czyk (part­ner at Bridges Fund Man­age­ment).